This study reported clinical outcomes of 44 patients treated with proton (89%) or carbon ion therapy (11%). At a median follow-up of 34.3 months, 2-, and 3-year actuarial LC rates were 95.5% and 90.9%. The 2-, and 3-year OS and PFS rates were 97.7%, 93.2%, 95.5% and 90.9%, respectively. No grade ≥3 toxicities were observed. There was no significant difference in outcome or side effect profile seen for proton versus carbon ion therapy.